📊 JUNS Key Takeaways
Is JUNS a Good Investment? Thesis Analysis
Jupiter Neurosciences exhibits critical financial distress with negative stockholders' equity of -$1.8M, negligible revenue of $21.8K, and massive operating losses of -$8.9M. Annual cash burn of $5.4M against $3.8M in cash reserves indicates less than 12 months of runway, with deteriorating losses accelerating year-over-year, signaling imminent solvency risk.
Why Buy JUNS? Key Strengths
- Cash position of $3.8M provides short-term operational runway
- High gross margin of 80.6% demonstrates operational efficiency on generated revenue
- Pharmaceutical sector exposure offers potential for significant upside if development candidates succeed
JUNS Investment Risks to Consider
- Negative stockholders' equity of -$1.8M indicates technical insolvency and liquidation risk
- Accelerating losses with net income deteriorating 254.4% year-over-year
- Severe cash burn of $5.4M annually with less than 12 months of runway before depletion
- Current ratio of 0.65x and working capital deficit indicate acute liquidity crisis
- Negligible revenue generation with no evidence of near-term path to commercialization
Key Metrics to Watch
- Monthly cash burn rate and total months of runway until capital exhaustion
- Progress on pipeline candidates and clinical trial milestones toward revenue generation
- Equity financing activities, dilution rate, and ability to extend runway
JUNS Financial Metrics
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
JUNS Profitability Ratios
JUNS vs Healthcare Sector
How JUPITER NEUROSCIENCES, INC. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is JUNS Overvalued or Undervalued?
Based on fundamental analysis, JUPITER NEUROSCIENCES, INC. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
JUNS Balance Sheet & Liquidity
JUNS 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: JUPITER NEUROSCIENCES, INC.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-0.08 indicates the company is currently unprofitable.
JUNS Growth Metrics (YoY)
JUNS Capital Allocation
JUNS SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for JUPITER NEUROSCIENCES, INC. (CIK: 0001679628)
📋 Recent SEC Filings
❓ Frequently Asked Questions about JUNS
What is the AI rating for JUNS?
JUPITER NEUROSCIENCES, INC. (JUNS) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are JUNS's key strengths?
Claude: Cash position of $3.8M provides short-term operational runway. High gross margin of 80.6% demonstrates operational efficiency on generated revenue.
What are the risks of investing in JUNS?
Claude: Negative stockholders' equity of -$1.8M indicates technical insolvency and liquidation risk. Accelerating losses with net income deteriorating 254.4% year-over-year.
What is JUNS's revenue and growth?
JUPITER NEUROSCIENCES, INC. reported revenue of $21.8K.
Does JUNS pay dividends?
JUPITER NEUROSCIENCES, INC. does not currently pay dividends.
Where can I find JUNS SEC filings?
Official SEC filings for JUPITER NEUROSCIENCES, INC. (CIK: 0001679628) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is JUNS's EPS?
JUPITER NEUROSCIENCES, INC. has a diluted EPS of $-0.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is JUNS a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, JUPITER NEUROSCIENCES, INC. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is JUNS stock overvalued or undervalued?
Valuation metrics for JUNS: ROE of N/A (sector avg: 15%), net margin of -39,662.8% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy JUNS stock in 2026?
Our dual AI analysis gives JUPITER NEUROSCIENCES, INC. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is JUNS's free cash flow?
JUPITER NEUROSCIENCES, INC.'s operating cash flow is $-5.4M, with capital expenditures of N/A. FCF margin is -24,838.2%.
How does JUNS compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -39,662.8% (avg: 12%), ROE N/A (avg: 15%), current ratio 0.65 (avg: 2).